Physician profile
Syed Ali
NPI 1588664775
$3,607.78
in general payments reported to CMS, 2019-2025
23 companies · $238 in 2025
The $238 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $665 · 2021: $822 · 2022: $536 · 2023: $339 · 2024: $214 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $946.47 | 2020-2025 | Glassia |
| Grifols USA, LLC | $403.01 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.33 | 2019-2024 | Stiolto Respimat, Spiriva Respimat |
| Mylan Specialty L.P. | $288.72 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals Lp | $286.07 | 2019-2025 | Fasenra, Airsupra |
| Philips North America LLC | $190.41 | 2019-2023 | |
| Harmony Biosciences LLC | $183.19 | 2020-2025 | |
| Glaxosmithkline, LLC. | $163.47 | 2019-2025 | Nucala, Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $139.67 | 2019 | |
| Jazz Pharmaceuticals INC. | $107.75 | 2019-2022 | |
| Pulmonx Corporation | $100.55 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $90.63 | 2019-2020 | |
| Genzyme Corporation | $84.11 | 2019-2025 | |
| Shire North American Group INC | $71.69 | 2019 | |
| Insmed, INC. | $53.60 | 2022-2025 | Arikayce |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $46.38 | 2019 | |
| United Therapeutics Corporation | $33.02 | 2021-2022 | |
| Abbvie INC. | $29.96 | 2022 | |
| Viatris Specialty LLC | $21.40 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $20.76 | 2023 | Sunosi |
| Merck Sharp & Dohme LLC | $20.48 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $20.25 | 2020 | |
| Pfizer INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.